The AECC has awarded the following grants to IDIBAPS in 2024:
- ASPIRE-AECC project: call for the AECC 70% survivorship challenge
- The six-year project aims to conduct a randomised clinical trial to increase the survival window in patients with early-stage hepatocellular carcinoma who are at a high risk of developing a new tumour after surgical removal. To do so, immunotherapy (atezolizumab plus bevacizumab) will be administered before and after tumour surgery and thereby promote a stronger antitumor immune response. The project is coordinated by Josep Maria Llovet, the head of the IDIBAPS research group Translational research in hepatic oncology and José R Bustelo, from the CIC – University of Salamanca. IDIBAPS’ part of the project has received €8 million in funding. For further information, please click here.
- The six-year project aims to conduct a randomised clinical trial to increase the survival window in patients with early-stage hepatocellular carcinoma who are at a high risk of developing a new tumour after surgical removal. To do so, immunotherapy (atezolizumab plus bevacizumab) will be administered before and after tumour surgery and thereby promote a stronger antitumor immune response. The project is coordinated by Josep Maria Llovet, the head of the IDIBAPS research group Translational research in hepatic oncology and José R Bustelo, from the CIC – University of Salamanca. IDIBAPS’ part of the project has received €8 million in funding. For further information, please click here.
- AECC-IDIBAPS Excellence Programme: Immunotherapy against cancer. Call for applications for the AECC Excellence Programme 2024
- This programme will conduct cutting-edge studies to understand the biology of tumours and their environment. The goal is to decipher why some people with liver cancer, breast cancer, or lymphoid tumours do not respond to immunotherapy treatment and why the disease recurs after a while. The principal investigator is Elías Campo, the director of IDIBAPs and the head of its research group Molecular pathology of lymphoid neoplasms. The project has received €2 million in funding. For further information, please click here.
- This programme will conduct cutting-edge studies to understand the biology of tumours and their environment. The goal is to decipher why some people with liver cancer, breast cancer, or lymphoid tumours do not respond to immunotherapy treatment and why the disease recurs after a while. The principal investigator is Elías Campo, the director of IDIBAPs and the head of its research group Molecular pathology of lymphoid neoplasms. The project has received €2 million in funding. For further information, please click here.
- Impact of chronic stress on immunosuppression in lung cancer through alterations in tumour-associated fibroblasts. Call: TRANSCAN 3 – JTC 2023
- This international project seeks to understand how chronic stress affects the immune system in lung cancer and makes immunotherapy less effective. The ultimate goal is to identify new treatment strategies for these patients. The principal investigator is Noemí Reguart, a member of the IDIBAPS research group Translational genomics and targeted therapies in solid tumours. The project has received €55,370 in funding.
- This international project seeks to understand how chronic stress affects the immune system in lung cancer and makes immunotherapy less effective. The ultimate goal is to identify new treatment strategies for these patients. The principal investigator is Noemí Reguart, a member of the IDIBAPS research group Translational genomics and targeted therapies in solid tumours. The project has received €55,370 in funding.
- Exploring oncogenic hyperactivation as a new therapeutic strategy in mantle cell lymphoma. AECC 2024 postdoctoral grant
- Beneficiary: Neus Roca, postdoctoral investigator in the research group Molecular pathology of lymphoid neoplasms.
- Grant: €160,000
- AECC Laboratory Internships Grant Programme for the Academic Year 2024
- Beneficiary: Albert Boladeras
- Grant: €3,872,720
IDIBAPS-Hospital Clínic has 25 research groups that address the main challenges of oncology, from developing new treatments and diagnostic tests to understanding the biological mechanisms of cancer. These groups include experts in clinical oncology, translational research and basic sciences and coordinate their work to ensure a real impact on patients. The research groups at IDIBAPS-Hospital Clínic publish around 450 scientific articles on cancer each year. They also lead important national and international projects on the subject. For further information, please click here.
IDIBAPS also plays a prominent role in the new Clínic Barcelona Comprehensive Cancer Centre, an organisational and multidisciplinary structure that allows cancer to be addressed from all areas, guaranteeing personalised care based on the best scientific evidence. It also facilitates the rapid incorporation of innovations and new diagnostic tests whilst promoting the development of new therapies, including cellular immunotherapy therapies, and training programmes for current and future professionals.
